EOC Pharma

  • EOC Pharma’s Entinostat Tablets approved for marketing by China NMPA

    April 24, 2024,  Entinostat Tablets  (trade name: Jingzhuda), a Class 1 innovative drug developed by EOC Pharma, was officially approved by the China NMPA[1]https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240430142236103.html. Entinostat Tablets is indicated for combination with aromatase inhibitors for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative locally advanced or metastatic breast cancer that has recurred or progressed after endocrine therapy. Entinostat is the first innovative drug developed by EOC Pharma. Entinostat works to regulate histone hyper-acetylation and promote transcriptional activation of specific genes by selectively inhibiting class I…